Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor

Japanese Journal of Cancer Research

Volumn 90, Issue 1, 1999, Pages 93-100

  Asano, Makoto ^a   Yukita, Ayako ^a   Suzuki, Hideo ^a  

^a Base Technology Center   (Japan)

Author keywords

Antitumor activity; Monoclonal antibody; Nude mice; VEGF; Xenograft

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL GROWTH; COLON TUMOR; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; LUNG TUMOR; MELANOMA; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR VOLUME;

EID: 0033043733     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00671.x     Document Type: Article

References (36)

1. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43, 175-203 (1985).
2. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82, 4-6 (1990).
3. Folkman, J. and Klagsbrun, M. Angiogenic factors. Science, 235, 442-447 (1987).
4. Klagsbrun, M. and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53, 217-239 (1991).
5. Folkman, J. and Shing, Y. Angiogenesis. J. Biol. Chem., 267, 10931-10934 (1992).
6. Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V. and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309 (1989).
7. Senger, D. R., Galli, S. J., Dvorak, A. M. Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. xumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983-985 (1983).
8. Plöuet, J., Schilling, J. and Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J., 8, 3801-3806 (1989).
9. Plate, K. H., Breier, G., Weich, H. A. and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-848 (1992).
10. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S. and Nose, T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patient. Cancer Res., 56, 2185-2190 (1996).
11. Mattern, J., Koomagi, R. and Volm, M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int. J. Oncol., 6, 1059-1062 (1995).
12. Toi, M., Inada, K., Suzuki, H. and Tominaga, T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat., 36, 193-204 (1995).
13. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R. and Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55, 3964-3968 (1995).
14. Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T. and Terada, M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54, 4233-4237 (1994).
15. Guidi, A. J., Abu-Jawdeh, G., Berse, B., Jakeman, R. W., Tognazzi, K., Dvorak, H. F. and Brown, L. F. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst., 87, 1237-1245 (1995).
16. Mise, M., Arai, S., Higashituji, H., Furutani, M., Niwano, M., Harada, T., Ishigami, S., Toda, Y., Nakayama, H., Fukumoto, M., Fujita, J. and Imamnra, M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology, 23, 455-464 (1996).
17. Boocock, C. A., Charnock-Jones, D. S., Sharkey, A. M., McLaren, J., Barker, P. J., Wright, K. A., Twentyman, P. R. and Smith, S. K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst., 87, 506-516 (1995).
18. Kondo, S., Asano, M. and Suzuki, H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem. Biophys. Res. Commun., 194, 1234-1241 (1993).
19. Kondo, S., Asano, M., Matsuo, K., Ohmori, I. and Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta. 1221, 211-214 (1994).
20. Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., Yoshida, M., Ikeda, T. and Tominaga, T. Concentration of vascular endothelial growth factor in the sera of normal control and cancer patients. Clin. Cancer Res., 2, 821-826 (1996).
21. Yeo, K.-T., Wang, H. H., Nagy, J. A., Sioussat, T. M., Ledbetter, S. R., Hoogewerf, A. J., Zhou, Y., Masse, E. M., Senger, D. R., Dvorak, H. F. and Yeo, T.-K. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res., 53, 2912-2918 (1993).
22. 121. Cancer Res., 55, 5296-5301 (1995).
23. 121). Hybridoma, 14, 475-480 (1995).
24. Asano, M., Yukita, A., Matsumoto, H., Hanatani, M. and Suzuki, H. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma, 17, 185-190 (1998).
25. 121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochim. Biophys. Acta. 1243, 195-202 (1995).
26. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844 (1993).
27. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N. and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991 (1992).
28. Terman, B. I., Vermazen, M. D., Carrion, M. E., Dimitrov, D., Armellino, D. T., Gospodsrowicz, D. and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun., 187, 1579-1585 (1992).
29. Waltenherger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. and Heldin, C.-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269, 26988-26995 (1994).
30. Gitay-Goren, H., Halaban, R. and Neufeld, G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptor. Biochem. Biophys. Res. Commun., 190, 702-709 (1993).
31. Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. and Satow, Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res., 55, 5687-5692 (1995).
32. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. and Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 92, 735-745 (1998).
33. Warren, R. S., Yuan, H., Matil, M. R., Gillett, N. A. and Ferrara, N. Regulation of vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental metastasis. J. Clin. Invest., 95, 1789-1797 (1995).
34. Melnyk, O., Shuman, M. A. and Kim, K. J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res., 56, 921-924 (1996).
35. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367, 576-579 (1994).
36. Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A. and Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56, 1615-1620 (1996).